Skip to main content
. 2023 May 6;15(9):3644–3677. doi: 10.18632/aging.204697

Figure 6.

Figure 6

FAM46C was related to LDH level and clinical therapy in in multiple myeloma patients. (A) The comparison of clinical information between FAM46C-low and FAM46C-high group. (B) FAM46C was related to bortezomib and dexamethasone therapy in multiple myeloma patients. Left, bortezomib, P = 0.03, Chi-square test, two sided. Right, dexamethasone, P = 0.048, Chi-square test, two sided.